Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CK-666 is a cell-permeable, selective small molecule inhibitor of the actin-related protein 2/3 (Arp2/3) complex. It was discovered through high-throughput screening of a small molecule library by Cytokinetics in collaboration with Yale University. CK-666 binds to a pocket at the interface between the Arp2 and Arp3 subunits, stabilizing the complex in its inactive conformation and preventing the structural transition into the active, short-pitch conformation required for branched actin filament nucleation. It is widely used as a chemical probe in cell biology research to study actin cytoskeleton dynamics, cell migration, endocytosis, and intracellular pathogen motility (such as *Listeria monocytogenes*).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CK-666.